☆ 4.6 Letter

Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia

HAEMATOLOGICA (2016)

Journal

HAEMATOLOGICA

Volume 101, Issue 11, Pages E457-E460

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.2016.148999

Keywords

-

Categories

Hematology

Funding

NIH/NCI [P30 CA008748]
Susan and Peter Solomon Genomics Program at Memorial Sloan Kettering Cancer Center

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Review Oncology

Hypomethylating Agent-Based Combination Therapies to Treat Post-Hematopoietic Stem Cell Transplant Relapse of Acute Myeloid Leukemia

Giulia Ciotti, Giovanni Marconi, Giovanni Martinelli

Summary: Allogeneic stem cell transplantation is a preferred treatment for acute myeloid leukemia, but relapse rates are high. Hypomethylating agents (HMAs) show promise as a backbone for combination therapies, particularly in combination with donor lymphocyte infusion (DLI). Other combination strategies with lenalidomide and tyrosine kinase inhibitors have shown competitive response rates. However, gemtuzumab ozogamicin and immune checkpoint inhibitors have shown less promising results. Furthermore, investigation into histone deacetylase inhibitors and isocitrate dehydrogenase 1 and 2 (IDH1/2) inhibitors as combination strategies is needed.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Review Oncology

Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Kah Keng Wong, Rosline Hassan, Nik Soriani Yaacob

Summary: Decitabine and guadecitabine are hypomethylating agents that enhance anti-tumor immunity in AML and MDS patients by upregulating cancer/testis antigens, stimulating T cells, and inducing immune checkpoint molecules expression. Combining these agents with cancer vaccines or immune checkpoint blockade therapy shows promising efficacy in treating relapsed/refractory AML and high-risk MDS cases.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology

Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia

Audrey Delmas, Laurie Batchelder, Ira Arora, Solene Bayet, David Bruhn, Alice Eberhardt, Stephanie Philpott, Ana Maria Rodriguez-Leboeuf

Summary: This study explored patient preferences for different modes of administration (MOA) and the relative importance of treatment-related characteristics that influence treatment decisions in patients with AML. The majority of patients preferred oral administration due to convenience and considered efficacy and side effects as the most important factors in treatment decisions.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Hematology

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response

Petya Apostolova, Stefanie Kreutmair, Cristina Toffalori, Marco Punta, Susanne Unger, Ann-Cathrin Burk, Claudia Wehr, Kristina Maas-Bauer, Wolfgang Melchinger, Eileen Haring, Rouven Hoefflin, Khalid Shoumariyeh, Valerie Hupfer, Eliza Maria Lauer, Sandra Duquesne, Theresa Lowinus, Nicolas Gonzalo Nunez, Chiara Alberti, Sara da Costa Pereira, Carla Helena Merten, Laura Power, Matthias Weiss, Caroline Boeke, Dietmar Pfeifer, Reinhard Marks, Hartmut Bertz, Ralph Waesch, Gabriele Ihorst, Bernhard Gentner, Justus Duyster, Melanie Boerries, Geoffroy Andrieux, Juergen Finke, Burkhard Becher, Luca Vago, Robert Zeiser

Summary: The combination of HMA and the anti-PD-1 antibody nivolumab induces anti-AML immune responses in selected patients after allo-HCT and could serve as a bridging approach to a second allo-HCT.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Add to Collection

Review Immunology

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Johanna Rausch, Evelyn Ullrich, Michael W. M. Kuehn

Summary: AML is a malignant disease that is difficult to treat, especially in patients who cannot undergo intensive chemotherapy. Immunotherapy has been successful in treating solid tumors and lymphatic neoplasms, but its efficacy in AML has been limited. Epigenetic dysregulation is a driver of leukemogenesis, and combining targeted epigenetic drugs with immunotherapy may improve treatment outcomes. Further research is needed to understand the immune functions affected by these drugs and their potential for clinical use.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Review Biochemistry & Molecular Biology

The Immuno-Oncology and Genomic Aspects of DNA-Hypomethylating Therapeutics in Acute Myeloid Leukemia

Akiko Urabe, SungGi Chi, Yosuke Minami

Summary: Hypomethylating agents (HMAs) have been used for a long time in the treatment of hematologic neoplasms. Recent studies have shown their potential in combination with targeted agents and immune-checkpoint inhibitors. This review discusses the immuno-oncological backgrounds, therapeutic mechanisms, and current clinical trials of HMAs and/or venetoclax-based combination therapies in leukemia.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Add to Collection

Article Biochemistry & Molecular Biology

Development of a scoring system for predicting primary resistance to venetoclax plus hypomethylating agents (HMAs) in acute myeloid leukemia patients

Lihong Zong, Minyue Yin, Jinyu Kong, Jian Zhang, Baoquan Song, Jinzhou Zhu, Shengli Xue, Xiaojin Wu, Depei Wu, Xiebing Bao, Huiying Qiu

Summary: A scoring system was developed to predict the resistance of acute myeloid leukemia (AML) patients to the combination therapy of VEN and HMAs. Factors including FAB-M5, MDS-sAML, RUNX1-RUNX1T1, and FLT3-ITDm were identified as key predictors. The scoring system can provide better guidance for clinical treatment.

MOLECULAR CARCINOGENESIS (2023)

Add to Collection

Review Pharmacology & Pharmacy

Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia

Kristina Simonicova, Lubos Janotka, Helena Kavcova, Zdena Sulova, Albert Breier, Lucia Messingerova

Summary: Resistance to hypomethylating agents is a major obstacle in the treatment of elderly patients with MDS and AML, with approximately 50% of patients not responding due to intrinsic resistance. Various mechanisms such as changes in drug transport, metabolism, and DNA repair contribute to drug resistance, highlighting the need for further research to address this issue.

DRUG RESISTANCE UPDATES (2022)

Add to Collection

Article Oncology

Inpatient versus outpatient hypomethylating agent induction for acute myeloid leukemia as a predictor for survival

Chetan Jeurkar, Lindsay Wilde, Benjamin E. Leiby, Joshua Banks, Margaret Kasner, Gina Keiffer, Joanne Filicko-O'Hara, Neil Palmisiano

Summary: The study compared 100-day survival differences between inpatient and outpatient administration of hypomethylating agents in AML patients, showing that inpatient induction was associated with significantly lower odds of survival.

LEUKEMIA RESEARCH (2021)

Add to Collection

Review Oncology

Resistance to Hypomethylating Agents in Myelodysplastic Syndrome and Acute Myeloid Leukemia From Clinical Data and Molecular Mechanism

Guangjie Zhao, Qian Wang, Shuang Li, Xiaoqin Wang

Summary: Nucleoside analogs decitabine and azacitidine have shown significant improvement in cancer patient survival rates, but only around 50% of patients respond to them, and the mechanisms of resistance are still unknown.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Letter Hematology

Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival

Omer Karrar, Maymona Abdelmagid, Masooma Rana, Moazah Iftikhar, Kristen McCullough, Aref Al-Kali, Hassan B. Alkhateeb, Kebede H. Begna, Michelle A. Elliott, Abhishek Mangaonkar, Antoine Saliba, Mehrdad Hefazi Torghabeh, Mark R. Litzow, William Hogan, Mithun Shah, Mrinal M. Patnaik, Animesh Pardanani, Talha Badar, Hemant Murthy, James Foran, Jeanne Palmer, Lisa Sproat, Nandita Khera, Cecilia Arana Yi, Ayalew Tefferi, Naseema Gangat

Summary: This study examined the impact of different dosing schedules of venetoclax on overall survival and treatment response rates in newly diagnosed acute myeloid leukemia patients.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Health Care Sciences & Services

Effective Prognostic Model for Therapy Response Prediction in Acute Myeloid Leukemia Patients

Maria A. Kolesnikova, Aleksandra V. Sen'kova, Tatiana I. Pospelova, Marina A. Zenkova

Summary: Acute myeloid leukemia (AML) is a hematopoietic disorder with extremely short survival. The response to therapy and overall survival in AML patients is influenced by various patient- and tumor-associated factors, including tumor cell resistance to chemotherapeutic agents. In this study, a new prognostic scale based on multiple factors was developed to stratify AML patients and predict their treatment response and survival outcomes.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Add to Collection

Article Hematology

Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

Sandy On, Carolyn G. Rath, Michelle Lan, Bobby Wu, Kimberly M. Lau, Edna Cheung, William Alegria, Rebecca Young, Marisela Tan, Carrie Kim, Jennifer Phun, Nimish Patel, Gabriel Mannis, Aaron C. Logan, Vanessa Kennedy, Aaron Goodman, Randy A. Taplitz, Patricia A. Young, Raymond Wen, Ila M. Saunders

Summary: This study investigated the incidence of invasive fungal infections and other infectious complications in patients with acute myeloid leukaemia receiving venetoclax and hypomethylating agent therapy. The results showed a low incidence of IFIs, but an increase in bacterial infections and hospital admissions due to neutropenic fever.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Genetic characteristics predict response to venetoclax plus hypomethylating agents in relapsed or refractory acute myeloid leukemia

Guangyang Weng, Yu Zhang, Guopan Yu, Tingyue Luo, Sijian Yu, Na Xu, Zhiqiang Sun, Dongjun Lin, Lan Deng, Xinquan Liang, Jie Xiao, Hongyu Zhang, Ziwen Guo, Ruoyang Shao, Xin Du, Hua Jin, Qifa Liu

Summary: This study evaluated the efficacy of venetoclax combined with hypomethylating agents in R/R AML patients and identified potential genetic predictors of response. The results showed that venetoclax combined with hypomethylating agents was effective in R/R AML patients, and the response to treatment was associated with genetic characteristics.

JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Review Biochemistry & Molecular Biology

High-Risk Acute Myeloid Leukemia: A Pediatric Prospective

Fabiana Cacace, Rossella Iula, Danilo De Novellis, Valeria Caprioli, Maria Rosaria D'Amico, Giuseppina De Simone, Rosanna Cuccurullo, William G. Wierda, Kris Michael Mahadeo, Giuseppe Menna, Francesco Paolo Tambaro

Summary: Pediatric acute myeloid leukemia is a clonal disorder characterized by malignant transformation of the hematopoietic stem cell. Treatment includes chemotherapy and stem cell transplantation. Although prognosis has improved, it remains inferior to pediatric acute lymphoblastic leukemia.

BIOMEDICINES (2022)

Add to Collection

Article Hematology

Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Maximilian Stahl, Andriy Derkach, Noushin Farnoud, Jan Philipp Bewersdorf, Troy Robinson, Christopher Famulare, Christina Cho, Sean Devlin, Kamal Menghrajani, Minal A. Patel, Sheng F. Cai, Linde A. Miles, Robert L. Bowman, Mark B. Geyer, Andrew Dunbar, Zachary D. Epstein-Peterson, Erin McGovern, Jessica Schulman, Jacob L. Glass, Justin Taylor, Aaron D. Viny, Eytan M. Stein, Bartlomiej Getta, Maria E. Arcila, Qi Gao, Juliet Barker, Brian C. Shaffer, Esperanza B. Papadopoulos, Boglarka Gyurkocza, Miguel-Angel Perales, Omar Abdel-Wahab, Ross L. Levine, Sergio A. Giralt, Yanming Zhang, Wenbin Xiao, Nidhi Pai, Elli Papaemmanuil, Martin S. Tallman, Mikhail Roshal, Aaron D. Goldberg

Summary: Measurable residual disease (MRD) is a powerful prognostic factor in acute myeloid leukemia (AML). This study aims to identify pre-treatment molecular predictors of immunophenotypic MRD clearance in AML patients. The results showed that induction chemotherapy led to different MRD responses, with 35% achieving MRD- remission, 27% achieving MRD+ remission, and 38% having persistent disease. Subsequent therapy resulted in MRD conversion in 34% of MRD+ patients and 26% of patients with persistent disease. Specific gene mutations and karyotypic abnormalities were found to be associated with high or low rates of MRD- remission. Patients with fewer individual clones were more likely to achieve MRD- remission. Furthermore, the study demonstrated that achieving MRD- prior to allogeneic stem cell transplant (allo-SCT) was associated with favorable outcomes. Therefore, the inclusion of patients with specific baseline mutational patterns and high clone numbers in clinical trials should be considered.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Hematology

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes

Rami Komrokji, Luis E. Aguirre, Najla Al Ali, Mohamad Hussaini, David Sallman, Dana Rollison, Eric Padron

Summary: Hemolysis is a significant clinical feature in some patients with myelodysplastic syndromes (MDS). It is often caused by ineffective erythropoiesis or acquired defects in red blood cell (RBC) membrane. This study found that 10% of MDS patients had hemolysis, which was mostly nonimmune. Patients with hemolysis had lower survival rates, decreased response to erythropoiesis-stimulating agents, and higher response to hypomethylating agents. They also had higher prevalence of U2AF1 and EZH2 hotspot mutations, suggesting a role of splicing factor mutations in the development of hemolysis in MDS.

BLOOD ADVANCES (2023)

Add to Collection

Editorial Material Hematology

Venetoclax and hypomethylating agent therapy in myelodysplastic syndromes: Big picture perspective

Naseema Gangat, Rami S. Komrokji, Ayalew Tefferi

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms

Lindsay M. Gurska, Rachel Okabe, Alexandra Schurer, Meng Maxine Tong, Mark Soto, Daniel Choi, Kristina Ames, Shira Glushakow-Smith, Allison Montoya, Ellen Tein, Linde A. Miles, Haiying Cheng, Pamela Hankey-Giblin, Ross L. Levine, Swati Goel, Balazs Halmos, Kira Gritsman

Summary: The study found that crizotinib could suppress the activation of the JAK/STAT signaling pathway and decrease the disease burden of MPN. Additionally, crizotinib could overcome the persistence of JAK inhibitors by disrupting the interaction between RON kinase and JAK2. This research suggests that crizotinib should be further explored as a potential treatment for patients with MPN.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Review Oncology

SOHO State of the Art Updates and Next Questions: Treatment of Lower Risk Myelodysplastic Syndromes

Virginia O. Volpe, Guillermo Garcia-Manero, Rami S. Komrokji

Summary: MDS is a stem cell neoplasm with varying risk levels, and most patients suffer from complications related to cytopenia. Anemia is a hallmark of the disease and commonly requires treatment. Different approaches, such as erythroid stimulating agents and targeted drugs, can effectively improve cytopenias in specific MDS patient populations. However, refractory cytopenias remain a challenge, and more treatment options are needed.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Add to Collection

Article Multidisciplinary Sciences

Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells

Jerome Fortin, Ming-Feng Chiang, Cem Meydan, Jonathan Foox, Parameswaran Ramachandran, Julie Leca, Francois Lemonnier, Wanda Y. Li, Miki S. Gams, Takashi Sakamoto, Mandy Chu, Chantal Tobin, Eric Laugesen, Troy M. Robinson, Annick You-Ten, Daniel J. Butler, Thorsten Berger, Mark D. Minden, Ross L. Levine, Cynthia J. Guidos, Ari M. Melnick, Christopher E. Mason, Tak W. Maka

Summary: Mutations in IDH1, IDH2, and TET2 genes are commonly observed in myeloid neoplasms. These mutations have unexpected, distinct effects on hematopoietic stem and progenitor cells, contrary to previous expectations. Understanding these molecular alterations could lead to the development of more effective, genotype-specific therapies.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

Add to Collection

Editorial Material Oncology

Oncogenic IDH1 Mutation Imparts Therapeutically Targetable Metabolic Dysfunction in Multiple Tumor Types

Troy M. Robinson, Ross L. Levine

Summary: In this study, the researchers used mass spectrometry metabolomics, stable isotope labeling, and functional studies to investigate metabolic vulnerabilities in cancers with mutations in isocitrate dehydrogenase (IDH). They provide compelling evidence that dysregulated lipid synthesis is a synthetic lethal target in cancers with IDH1 mutations, but not IDH2 mutations.

CANCER DISCOVERY (2023)

Add to Collection

Article Hematology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis

Andrew J. Dunbar, Dongjoo Kim, Min Lu, Mirko Farina, Robert L. Bowman, Julie L. Yang, Young Park, Abdul Karzai, Wenbin Xiao, Zach Zaroogian, Kavi O'Connor, Shoron Mowla, Francesca Gobbo, Paola Verachi, Fabrizio Martelli, Giuseppe Sarli, Lijuan Xia, Nada Elmansy, Maria Kleppe, Zhuo Chen, Yang Xiao, Erin McGovern, Jenna Snyder, Aishwarya Krishnan, Corrine Hill, Keith Cordner, Anouar Zouak, Mohamed E. Salama, Jayden Yohai, Eric Tucker, Jonathan Chen, Jing Zhou, Timothy McConnell, Anna R. Migliaccio, Richard Koche, Raajit Rampal, Rong Fan, Ross L. Levine, Ronald Hoffman

Summary: Inflammatory signaling is crucial in the development of myelofibrosis (MF), a type of cancer. Recent studies have identified the involvement of JAK/STAT and NF-kappa B signaling in MF progression. This study further explores the role of CXCL8/CXCR2 signaling in MF pathogenesis, and highlights its potential as a therapeutic target.

BLOOD (2023)

Add to Collection

Article Oncology

Obesity in adult acute myeloid leukemia is not associated with inferior response or survival even when dose capping anthracyclines: An ECOG-ACRIN analysis

James M. Foran, Zhuoxin Sun, Catherine Lai, Hugo F. Fernandez, Larry D. Cripe, Rhett P. Ketterling, Janis Racevskis, Selina M. Luger, Elisabeth Paietta, Hillard M. Lazarus, Yanming Zhang, John M. Bennett, Ross L. Levine, Jacob M. Rowe, Mark R. Litzow, Martin S. Tallman

Summary: This study examined the association of obesity with AML and its impact on clinical outcomes. The results showed that obesity was associated with certain clinical and genetic features of AML, but did not affect patient survival.

CANCER (2023)

Add to Collection

Article Oncology

Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial

Vu H. Duong, Amy S. Ruppert, Alice S. Mims, Uma Borate, Eytan M. Stein, Maria R. Baer, Wendy Stock, Tibor Kovacsovics, William Blum, Martha L. Arellano, Gary J. Schiller, Rebecca L. Olin, James M. Foran, Mark R. Litzow, Tara L. Lin, Prapti A. Patel, Matthew C. Foster, Robert L. Redner, Zeina Al-Mansour, Christopher R. Cogle, Ronan T. Swords, Robert H. Collins, Jo-Anne Vergilio, Nyla A. Heerema, Leonard Rosenberg, Ashley O. Yocum, Sonja Marcus, Timothy Chen, Franchesca Druggan, Mona Stefanos, Theophilus J. Gana, Abigail B. Shoben, Brian J. Druker, Amy Burd, John C. Byrd, Ross L. Levine, Michael M. Boyiadzis

Summary: This study evaluated the efficacy of entospletinib, an oral inhibitor of spleen tyrosine kinase, combined with decitabine in patients with acute myeloid leukemia (AML) who have poor prognosis. The combination showed some activity and acceptable tolerance, but the complete remission rates were low and overall survival was short.

CANCER (2023)

Add to Collection

Review Hematology

Telomerase-targeted therapies in myeloid malignancies

Julian A. Waksal, Claudia Bruedigam, Rami S. Komrokji, Catriona H. M. Jamieson, John O. Mascarenhas

Summary: Human telomeres are repetitive sequences at the ends of chromosomes, playing important roles in preserving genomic integrity and preventing loss of genetic information. Telomerase, an enzyme involved in maintaining telomere length, is upregulated in malignant cells, making it a potential target for cancer therapy. This review focuses on the biology of telomeres and telomerase, and discusses the development of telomerase-targeted therapeutic candidates, particularly imetelstat, which has shown promising results in myeloid malignancies.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study

Gregory A. Abel, Donnie Hebert, Cecilia Lee, Dana Rollison, Nancy Gillis, Rami Komrokji, James M. Foran, Jane Jijun Liu, Tareq Al Baghdadi, Joachim Deeg, Steven Gore, Wael Saber, Steffanie Wilson, Michael Otterstatter, Jason Thompson, Christine Borchert, Eric Padron, Amy DeZern, David Cella, Mikkael A. Sekeres

Summary: This study investigates the impact of myelodysplastic syndromes (MDS) and other cytopenic states on health-related quality of life (HRQoL) and vulnerability. The findings show that patients with cytopenias undergoing MDS evaluation have similar HRQoL, regardless of the eventual diagnosis, but vulnerable individuals have worse HRQoL. Among MDS patients, lower-risk disease is associated with better HRQoL, except in vulnerable individuals.

BLOOD ADVANCES (2023)

Add to Collection

Article Hematology

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes

Rami S. Komrokji, Luis E. Aguirre, Najla H. Al Ali, Onyee Chan, Zhuoer Xie, Andrew Kuykendall, Kendra Sweet, Jeffrey E. Lancet, Eric Padron, David A. Sallman

BLOOD ADVANCES (2023)

Add to Collection

Letter Oncology

Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts

Uwe Platzbecker, Valeria Santini, Rami S. Komrokji, Amer M. Zeidan, Guillermo Garcia-Manero, Rena Buckstein, Dimana Miteva, Karen Keeperman, Natalia Holot, Jose Alberto Nadal, Yinzhi Lai, Sadanand Vodala, Barbara Rosettani, Ana Carolina Giuseppi, Aylin Yucel, Pierre Fenaux

LEUKEMIA (2023)

Add to Collection

Article Hematology

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Umeshkumar Vekariya, Monika Toma, Margaret Nieborowska-Skorska, Bac Viet Le, Marie-Christine Caron, Anna-Mariya Kukuyan, Katherine Sullivan-Reed, Paulina Podszywalow-Bartnicka, Kumaraswamy N. Chitrala, Jessica Atkins, Malgorzata Drzewiecka, Wanjuan Feng, Joe Chan, Srinivas Chatla, Konstantin Golovine, Jaroslav Jelinek, Tomasz Sliwinski, Jayashri Ghosh, Ksenia Matlawska-Wasowska, Gurushankar Chandramouly, Reza Nejati, Mariusz Wasik, Stephen M. Sykes, Katarzyna Piwocka, Emir Hadzijusufovic, Peter Valent, Richard T. Pomerantz, George Morton, Wayne Childers, Huaqing Zhao, Elisabeth M. Paietta, Ross L. Levine, Martin S. Tallman, Hugo F. Fernandez, Mark R. Litzow, Gaorav P. Gupta, Jean-Yves Masson, Tomasz Skorski

Summary: Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. Formaldehyde generated by serine/1-carbon cycle metabolism contributes to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells. Oncogenic tyrosine kinases (OTKs) enhance the expression of DNA polymerase theta (POL theta) to repair DPC-containing DNA double-strand breaks. Inhibition of POL theta can be an effective therapeutic strategy for leukemia.

BLOOD (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.